Company / Shareholders' Equity
ENANTA PHARMACEUTICALS INC Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$128.8M
FY2025
5-year range
$128.8M / $462.5M
FY2021-FY2025
Trend
-59.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 4 consecutive years, from $462M in FY2021 to $129M in FY2025.
Based on SEC 10-K filings.
$129M in FY2025 with a 5-year CAGR of -20.0%.
Declined from $399M to $129M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -34.4%
- 5-Year CAGR
- -20.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's shareholders' equity has declined for 4 consecutive years.
- 5-year CAGR of -20.0%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 59.9% year-over-year.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $128.8M | -59.9% |
| FY2024 | $321.3M | -19.6% |
| FY2023 | $399.4M | -12.3% |
| FY2022 | $455.6M | -1.5% |
| FY2021 | $462.5M | +17.5% |
| FY2020 | $393.7M | +30.5% |
| FY2019 | $301.7M | +11.8% |
| FY2018 | $269.9M | +14.3% |
| FY2017 | $236.2M | +58.9% |
| FY2016 | $148.7M | +34.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026